Durable Responses, Safety in Atopic Dermatitis Treated With IL-13 Inhibitor
The interleukin (IL)-13 inhibitor tralokinumab (Adbry) for atopic dermatitis provided long-term disease control with a favorable safety profile and improved quality of life (QoL), data from two studies showed. Interim results from a long-term extension study showed that 82.5% of patients had at least 75% improvement in the Eczema Area and Severity Index (EASI-75) after […]